Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
“The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions,” said Winselow Tucker, President and General Manager, Lilly India.
“Our mission—to make life better for people around the world—drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities. With India facing a growing burden of type 2 diabetes and obesity, broader availability of Tirzepatide will ensure that more patients can benefit from this innovative therapy,” he added.
Lilly will manufacture and supply Yurpeak to Cipla, while Cipla will distribute and promote the brand across India. The product will be priced the same as Mounjaro, Lilly’s existing Tirzepatide brand.
Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, prescribed as an adjunct to diet and exercise for type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.
Yurpeak will be available in the KwikPen presentation a multi-dose, single-patient-use prefilled pen with four fixed doses, administered once weekly. The pen will be offered in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — allowing healthcare professionals to tailor treatment plans for individual patient needs.
Achin Gupta, global chief operating officer, Cipla, added, “At Cipla, we remain steadfast in our commitment to advancing patient care by facilitating access to the best of global scientific innovation. With the introduction of Yurpeak (Tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies.”
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.
Cipla reported 10.18% increase in consolidated net profit to Rs 1,297.62 crore on a 3.93% rise in total revenue from operations to Rs 6,957.47 crore in Q1 FY26 over Q1 FY25.
Shares of Cipla slipped 3.16% to currently trade at Rs 1,593.20 on the BSE.
Newgen Software Technologies Ltd, Cipla Ltd, V-Guard Industries Ltd, Polycab India Ltd are among the other stocks to see a surge in volumes on BSE today, 25 September 2025.
TVS Motor Company Ltd clocked volume of 89745 shares by 10:47 IST on BSE, a 7.6 times surge over two-week average daily volume of 11802 shares. The stock lost 0.98% to Rs.3,418.00. Volumes stood at 13626 shares in the last session.
Newgen Software Technologies Ltd notched up volume of 3.32 lakh shares by 10:47 IST on BSE, a 4.71 fold spurt over two-week average daily volume of 70613 shares. The stock rose 4.64% to Rs.915.05. Volumes stood at 27200 shares in the last session.
Cipla Ltd recorded volume of 73432 shares by 10:47 IST on BSE, a 2.96 times surge over two-week average daily volume of 24770 shares. The stock lost 0.50% to Rs.1,530.10. Volumes stood at 22269 shares in the last session.
V-Guard Industries Ltd saw volume of 4.55 lakh shares by 10:47 IST on BSE, a 2.21 fold spurt over two-week average daily volume of 2.06 lakh shares. The stock increased 3.38% to Rs.378.00. Volumes stood at 1.57 lakh shares in the last session.
Polycab India Ltd saw volume of 20047 shares by 10:47 IST on BSE, a 2.19 fold spurt over two-week average daily volume of 9139 shares. The stock dropped 0.75% to Rs.7,476.75. Volumes stood at 8064 shares in the last session.